Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released Feb 24, 2022, before the open
10-K filed Feb 24, 2022, 55 days after period end · 0001193125-22-051569
| Metric | Q4 2021 | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$64.55M | -$59.12M | -$27.74M | -$11.48M |
| EPS Diluted |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| -$3.78 |
| -$3.82 |
| -$1.80 |
| -$0.75 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.